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Abstract 
Background: The safety and efficacy of cardiac stem/progenitor cells (CSC) have been demonstrated in previous 
preclinical and clinical assays for heart failure. However, their optimal delivery route to the ischemic heart has not yet 
been assessed. This study was designed to determine by a non‑invasive imaging technique (PET/CT) the biodistri‑
bution and acute retention of allogeneic pig CSC implanted by two different delivery routes, intracoronary (IC) and 
intramyocardial (IM), in a swine preclinical model of chronic ischemia–reperfusion.
Methods: Ischemia–reperfusion was induced in six Goettingen hybrid minipigs by 90 min coronary artery occlu‑
sion followed by reperfusion. Thirty days later, animals were allocated to receive IC (n = 3) or NOGA®‑guided IM 
injection (n = 3) of 50 million of 18F‑FDG/GFP‑labeled allogeneic pig CSC. Acute retention was quantified by PET/CT 
4 h after injection and cell engraftment assessed by immunohistochemical quantification of GFP+ cells three days 
post‑injection.
Results: Biodistribution of 18F‑FDG‑labeled CSC was clearly visualized by PET/CT imaging and quantified. No statisti‑
cal differences in acute cell retention (percentage of injected dose, %ID) were found in the heart when cells were 
administered by NOGA®‑guided IM (13.4 ± 3.4%ID) or IC injections (17.4 ± 4.1%ID). Interestingly, engrafted CSC were 
histologically detected only after IM injection.
Conclusion: PET/CT imaging of 18F‑FDG‑labeled CSC allows quantifying biodistribution and acute retention of 
implanted cells in a clinically relevant pig model of chronic myocardial infarction. Similar levels of acute retention are 
achieved when cells are IM or IC administered. However, acute cell retention does not correlate with cell engraftment, 
which is improved by IM injection.
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Background
Cardiovascular diseases are the main cause of morbid-
ity and mortality worldwide, leading to approximately 
17 million deaths per year. Unfortunately, predictions 
are not favorable and it is estimated that by 2030 about 
24 million people will die from cardiovascular diseases, 
representing 42% of deaths world-wide [1]. Alternative 
therapies based on the application of stem cells have 
been examined in preclinical models and clinical trials 
in patients with heart failure [2, 3]. Among the different 
cell types employed, cardiac stem/progenitor cells (CSC) 
have demonstrated a remarkable potential to induce a 
beneficial effect after implantation in rodent and pig 
models of myocardial infarction (MI) [4–6]. Further-
more, their therapeutic effect has been shown in a clini-
cal trial performed in patients with heart failure [7].
Despite the reported benefits of stem cells, some of 
the divergent results observed in clinical trials have 
been explained by the low level of cell engraftment and 
the lack of precise knowledge of the mechanisms of cell 
mediated cardiac repair [8]. Delivery of stem cells either 
by an intracoronary (IC) route or directly by intramyo-
cardial injection (IM) has been associated with different 
degrees of cell retention (reviewed in [3]). In this sense, 
the use of three-dimensional electromechanical mapping 
(NOGA®) as a delivery system that allows targeting to 
the viable myocardium could favor cell engraftment [9, 
10] and could be of great use specially in the case of those 
patients where the coronary artery might be blocked 
impeding an IC delivery.
In order to compare different delivery approaches and 
cell types, methods are needed for monitoring stem cell 
grafts non-invasively, with sufficiently high sensitiv-
ity and specificity to determine the fate of transplanted 
cells. Molecular imaging techniques for in vivo cell track-
ing, such as labeling of cells with 2-deoxy-2-[18F]fluoro-
d-glucose (18F-FDG) that can be subsequently followed 
by means of positron emission tomography (PET), have 
been explored [11, 12]. This method allows cell tracking 
for a sufficient period of time (hours) to assess acute cell 
retention. Moreover, PET permits quantification of the 
images where an estimation of cell numbers in a specific 
organ can be obtained. This technique has successfully 
been applied for cell tracking in small and large animal 
models of MI [13–18].
In this study, the acute retention of allogeneic pig CSC 
has been assessed in a swine model of chronic MI using 
a cutting-edge PET/CT hybrid scanner. Acute retention 
of CSC was comparatively quantified when using two dif-
ferent cell delivery routes (IC and NOGA®-guided IM) 
and correlated with CSC engraftment three days post-
implantation by immunohistological detection of CSC.
Methods
Pig cardiac stem/progenitor cells isolation, GFP labeling 
and phenotypic characterization
CSC isolation, culture, characterization and green fluo-
rescent protein (GFP) lentiviral transduction were per-
formed by Coretherapix SLU as previously reported 
[6]. Briefly, starting material (~1  g of cardiac tissue) 
obtained from healthy female Gottingen minipig hearts 
was digested by combining mechanical dissociation with 
enzymatic digestion [collagenase type 2 (Worthington 
Biochemical Corporation)] to obtain a cell suspension. 
Cell suspension was immunodepleted of CD45-posi-
tive cells and immunoselected for CD117 (c-kit) using 
magnetic microbeads coupled with specific antibodies 
(Miltenyi Biotech). The resulting cells were seeded on pig 
gelatin (Sigma-Aldrich) coated plates and cultured in low 
O2 conditions (3%) using isolation medium (DMEM/F12 
with 10% FBS, l-glutamine, penicilline–streptomycine, 
insulin-transferrin-selenium (ITS) and bFGF, IGF-II, EGF 
and hEPO recombinant growth factors (Invitrogen™, 
Peprotech and Sigma-Aldrich)). One week after seeding, 
the medium was replaced by growing medium (DMEM/
F12 and Neurobasal medium (1:1) supplemented with 
10% FBS, l-Glutamine, Pen-Strep, ITS, growth fac-
tors (bFGF, IGF-II, EGF) together with B27, N2 and 
β-mercaptoethanol (Invitrogen™). Cells were expanded 
over 3 passages and then cryopreserved in medium with 
5% of DMSO.
Cells used in this assay were Green Fluorescent Protein 
(GFP) labeled at passage 4 with a bicistronic, self-inacti-
vating, lentiviral vector (pSIN-EF1-α-GFP-IRES-Puro) 
that expresses GFP and puromycin resistance genes 
under the control of an EF1α eukaryotic promoter. Len-
tiviral vector transduction of CSC, at passage P3/1, was 
performed by spinoculation (centrifugation at 1000×g 
for 1 h at 34  °C) of 1.7 ×  106  cells with 4.3 ml of lenti-
viral supernatant supplemented with 8  µg/ml of poly-
brene. Multiplicity of infection (MOI) was estimated to 
be 2.5  TU/cell. Transduction efficiency was measured 
by quantification of the GFP expression in positive cells 
compared to non-transduced CSC. GFP expression 
was analyzed in an EPICS® XL™ (Beckman Coulter) 
flow cytometer. GFP brightness, acceptable for in  vivo 
detection, was also visually evaluated by fluorescence 
microscopy (Nikon Eclipse TS100). Finally, phenotypic 
analysis of surface markers on GFP-labeled CSC was 
performed by resuspending 2  ×  105 cells in 100  µl of 
ice cold PBS containing 1% BSA and 1% human serum 
to be stained for 40 min at 4  °C in the dark and orbital 
shaker with combinations of following purified or conju-
gated mAb: purified CD11R3; purified CD29 and SLA-II 
(VMRD, Pullman, WA, USA) and PE-conjugated CD45, 
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FITC-conjugated CD90 and CD105 (BD Biosciences, San 
Jose, CA, USA). Background fluorescence was assessed 
using appropriate isotype- and fluorochrome-matched 
control mAbs (BD Biosciences) in parallel. Afterwards 
the cells were washed twice with PBS 0.1%-BSA buffer. 
Secondary antibody PE-conjugated anti mIgG1/mIgG2b 
(BD Biosciences) were added when needed for 15 min at 
4 °C, dark environment and shaking, followed by 2 cycles 
of cell washing. Finally, cells were resuspended in PBS 
0.1% BSA buffer to be analyzed by flow cytometry (Epics 
XL-MCL flow cytometer, Beckman Coulter, Fullerton, 
CA, USA) and FCS Express software.
18F‑FDG labeling of pig cardiac stem/progenitor cells
18F-FDG was optimized for labeling of 50  ×  106 cells, 
which were suspended in glucose-free DMEM supple-
mented with 5% human serum albumin and incubated 
with 18F-FDG (370  MBq/ml) at room temperature for 
60  min. Cells were then washed twice with PBS and 
resuspended in DMEM for implantation. Supernatant 
and pellet (cells) radioactivity were measured in a dose 
calibrator. A trypan blue viability test was performed to 
calculate cell viability before and after radiolabeling. To 
assess 18F-FDG efflux from CSC, the variation in radio-
activity in the supernatant was measured at 60, 90 and 
120  min post-labeling. This experiment was repeated 
four times.
MI and cell administration in adult Gottingen minipigs
Adult Goettingen hybrid minipigs (60–80  kg, n  =  6) 
were procured from our breeding center (GLP accred-
ited center at the University of Navarra, Spain) according 
to the legal and ethical requirements of EU legislation. 
In each procedure, swine were pre-medicated, induced, 
intubated and mechanically ventilated. Postopera-
tively, all animals received opioid patches, NSAIDs and 
antibiotics.
MI (ischemia–reperfusion) was provoked as previously 
described by our group [19, 20]. Briefly, an introducer 
sheath was placed by dissection in the left carotid artery 
and adjunct agents were intravenously administered 
prior to introducing the catheter. Under fluoroscopic 
guidance, a 7fr guiding catheter was positioned in the 
left coronary ostium and MI was induced by selectively 
delivering a balloon angioplasty catheter (via a micro-
catheter advanced through the guiding catheter to the 
anterior descendent artery (ADA) that was inflated for 
90 min. Coronary occlusion was demonstrated by coro-
nary angiography and ST-segment changes in the elec-
trocardiogram. Adjunct agents and advanced life support 
were used when needed. Finally, the delivery catheter was 
removed, the carotid artery ligated, and the cut down site 
sutured.
Thirty days post-MI, 50 million of allogeneic pig CSC-
GFP+ previously labeled with 18F-FDG (1.45 ± 0.8 MBq/
kg of 18F-FDG labelled cells) were transplanted by two 
different methods: percutaneously or IC. Percutane-
ous transplantation (n = 3) was performed by a NOGA 
injection catheter, advanced from the femoral artery and 
across the aortic valve. NOGA mapping guided intra-
myocardial transplantation was performed using the 
Myostar injection catheter (Bioscience-Webster) based 
on the generated 3D map of the heart; 50 million cells 
were resuspended in 9 ml of DMEM culture media and 
a total of 30 injections (300 μl/per injection) were slowly 
applied at each transplantation site. For intracoronary 
injection, cells were resuspended in 20 ml of DMEM.
PET/CT acquisition and analysis
Animals were imaged on a Biograph mCT PET scan-
ner (Siemens Medical Solutions, Hoffman Estates, IL, 
USA) 4  h after cell administration. A detailed descrip-
tion of this PET/CT system and its performance char-
acterization can be found elsewhere [21]. This scanner 
allows point spread function depth-dependent resolu-
tion recovery and time-of-flight acquisition and recon-
struction [22]. The acquisition protocol consisted of a 
whole-body CT scan for attenuation correction and a 
3D whole-body PET emission scan (5–6 bed positions, 
10  min per bed position). Images were reconstructed 
with the 3D-OP-OSEM + PSF algorithm with TOF with 
3 iterations and 21 subsets respectively (matrix sizes 
200 × 200 and a Gaussian post- reconstruction filter with 
FWHM = 2 mm).
Visual analysis of the CSC biodistribution was per-
formed using a workstation with True D software 
(Siemens Healthcare, Erlangen, Germany). For the quan-
titative analysis, all studies were exported and analyzed 
using the PMOD software (PMOD Technologies Ltd., 
Adliswil, Switzerland). A total-body volume of inter-
est (VOI) was drawn to measure the total activity in the 
body, expressed in KBq. Additional VOIs were drawn 
over heart, lungs, liver, spleen, kidneys and bladder. All 
the VOIs were created over CT images and then cop-
ied and pasted onto the corresponding PET images. 
The percentage of injected dose in the organs (%ID) was 
then calculated as the ratio of activity in the organ VOI 
and activity in the total-body VOI. Afterwards, con-
sidering the physiological distribution of 18F-FDG [23], 
the percentage of cell retention in the heart was calcu-
lated assuming that the signal produced by the cells was 
located exclusively at the heart and the lungs.
Histological processing and immunostaining
Three days after CSC administration, animals were sac-
rificed with pentobarbital and a saturated solution of 
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potassium chloride, and the heart was excised. Explanted 
tissues were fixed in formalin, cut in 2–4 cm2 blocks and 
paraffin embedded for histological analysis. Location of 
MI was visually assessed. Sampling of tissues consisted 
of scar surrounded by a ring of viable myocardium. After 
paraffin embedding, 5  μm sections were prepared from 
all blocks and stained for GFP to quantify the presence 
of engrafted CSC in the infarct and peri-infarct areas, as 
previously described [19]. Briefly, cell detection was per-
formed by immunohistochemical methods. A rabbit anti-
GFP (Invitrogen) was diluted 1:500 in TBS and used as 
first antibody. EnVision™-HRP conjugated system (Dako) 
was used as secondary reagent. High-power field images 
were acquired and GFP positive cells quantified using 
Image J software. A minimum of 40 sections per animal 
were analyzed for analysis. All microphotographs were 
obtained on a Nikon Eclipse E800 microscope and ana-
lyzed with a computarized system (Axiovision 4.6, Zeiss, 
Germany).
Statistical analysis
All data are expressed as mean  ±  SD. Comparisons 
between IC and IM data were performed using the 
Mann–Whitney U test. Statistical analysis was per-
formed with the StataIC 12 software and differences were 
considered statistically significant when p < 0.05.
Results
Pig cardiac stem/progenitor cells isolation 
and characterization
Pig CSC were isolated from the cardiac tissue of Gottin-
gen pigs and maintained in culture as previously reported 
[6]. CSC had an average size below 14  µm. Phenotypic 
characterization by flow cytometry revealed expression 
of CD105, CD90 and CD29 markers and no expression 
of the hematopoietic lineage markers CD45, CD11R3 or 
SLA-II (Fig. 1).
Radiolabeling of CSCs with 18F‑FDG
Radiolabeling did not induce a significant change in cell 
viability (−2 ± 4.6% of variation between CSC incubated 
with 18F-FDG and control cells). Efflux of 18F-FDG from 
cells was 32.4 ±  3.4% at 60  min. This release remained 
stable at 90 min (29.3 ± 2.2%) and 120 min (31.2 ± 2.5%).
Cell biodistribution and acute retention after IM and IC 
injection
Visual analysis of PET images showed the biodistribution 
of radioactivity 4  h after CSC administration, demon-
strating a high 18F-FDG activity in the heart (Fig. 2; see 
also Additional file 1: Video 1, Additional file 2: Video 2). 
The distribution of cells after IC administration showed a 
diffuse pattern through the vascular territory whereas IM 
delivery via NOGA® led to a focal uptake pattern over 
the myocardial wall, corresponding to the cell injection 
sites (Fig.  3). Radioactivity was also clearly observed in 
the lungs, whereas liver and spleen showed a slight sig-
nal. Due to the efflux of 18F-FDG from cells, physiologi-
cal excretion of free 18F-FDG was detected in kidneys, 
mainly in renal medulla, and bladder. Additionally, in 
four out of six animals, a high radioactivity concentration 
was detected in some mediastinal lymph nodes (Fig. 2). 
Quantitative analysis of images is summarized in Fig. 4a 
and Additional file 3: Table S1. No statistical differences 
in %ID were found between the IM and IC routes of 
administration in the different organs. The largest activ-
ity attributable to cells was located in the heart and no 
statistically significant differences in %ID were found 
between animals that received the cells IM (13.4 ± 3.4%) 
or IC (17.4 ± 4.1%) (p = 0.27). High values of %ID were 
also observed in lungs (IM 12.2 ± 3.5%; IC 11.3 ± 2.1%) 
(p = 0.82). The rest of the activity attributable to free-18F-
FDG was mainly located in the bladder (IM 15.2 ± 4.7%; 
IC 15.3 ± 2.9%) (p = 0.83), and to a lesser extent in the 
kidneys. Radioactivity accumulation in liver and spleen 
was very low in comparison with other organs.
Taking into account the physiological biodistribution 
of free 18FDG, and assuming that the vast majority of the 
cells were entrapped in heart and lungs, the percentage of 
retained cells in both organs was calculated considering 
only the radioactivity in these organs. By IM administra-
tion, 52.2 ± 13.3% of the cells were located in the heart, 
whereas this percentage was 60.2 ± 9.7% for IC admin-
istration (p  =  0.45). The percentage of cell retention 
in lungs was 47.8 ±  13.3 and 39.8 ±  9.7 for IM and IC 
administration respectively (p = 0.44).
Cell engraftment
Cell engraftment was analyzed three days post-trans-
plantation. Immunohistochemical analysis of GFP posi-
tive cells in the scar and perinfarcted areas revealed the 
presence in the myocardium of engrafted CSC in all the 
hearts that were implanted IM (8.9  ×  103, 23.4  ×  103, 
131.6  ×  103  cells/mm2). On the contrary, no positive 
cells were found after IC implant in any of the three pigs 
(Fig. 4b).
Discussion
The development of methods for non-invasively monitor-
ing stem cell distribution after transplantation in patients 
with cardiac diseases is a pre-requisite to compare dif-
ferent delivery systems and potentially, to improve our 
understanding of the underlying mechanisms. In this 
study, using a last generation PET/CT hybrid scan-
ner, we compared the tissue distribution and retention 
of allogeneic CSC in a large animal model of chronic 
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ischemia–reperfusion after two different cell delivery 
routes (NOGA®-guided IM and IC). The combination 
of PET and CT provided excellent images, significantly 
better than those obtained in previous studies in swine 
models of MI [16–18], which allowed more robust and 
reliable quantification of the implanted cells.
In this study, 50 million cells were injected in our 
chronic model of MI with no adverse effects detected 
during or after transplantation by either of the two deliv-
ery routes. Previous studies performed in pig acute and 
subacute infarct IC injected with 25 million CSC have 
also shown safety and also efficacy [6]. In our model, the 
quantified images showed that cell retention in heart was 
equivalent but with a clearly different pattern between 
IC and NOGA®-guided IM injection, which reflects 
the delivery route. Other studies have also compared by 
means of cell radiolabeling and imaging tracking several 
delivery methods for stem cells in MI animal models [13–
18]. Interestingly, Hou and collaborators directly com-
pared different delivery methods (IC, IM and interstitial 
retrograde coronary venous delivery) in a swine infarct 
model [16]. In this case, %ID values detected in heart 
were comparable to our results when IM injected (about 
12%). However, IC delivery and interstitial retrograde 
coronary venous delivery gave rise to somewhat lower 
retention values (about 3%). This discrepancy in the IC 
values between these two preclinical studies might well 
be due to methodological differences including cell type, 
time of post-infarction treatment and imaging methods 
that do not allow a direct comparison of the results.
Beside the heart, we detected a large accumulation of 
activity in bladder and kidneys (renal medulla), whereas 
Fig. 1 Pig CSC isolation and characterization: Scheme of the process followed to isolate pig CSC from cardiac tissue (a). Phenotypic characterization 
of CSC by flow cytometry. The percentage of positive cells with respect to the matched isotype control is indicated (b). Lentiviral GFP expression 
in CSC administered into infarcted pigs quantified by flow cytometry was 99.00 ± 0.04%. Representative pictures of CSC culture in dark field and 
under fluorescence microscopy (c)
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liver and spleen had a very low signal. Kidney and uri-
nary bladder activities reflected the excretion of free 
18F-FDG. Moreover, not unexpectedly, our results also 
showed that a large percentage of cells was retained in 
the lungs, also independently of the route of adminis-
tration. After an intravenous injection of free 18F-FDG, 
cardiac uptake is variable, but most frequently mild and 
always homogeneous; moreover, it is well known that the 
lungs normally exhibit very low 18F-FDG uptake [23]. 
Our images showed a different pattern of activity, so it 
can be assumed that the signal attributable to the radi-
olabeled cells is almost completely located in heart and 
Fig. 2 PET/CT images after 18F‑FDG labeled CSC administration: Images of IM (A, B) and IC (C, D) administration of 18F‑FDG‑labeled CSC in pigs. 
A and C correspond to PET maximal intensity projection (MIP) images, showing the distribution of 18F‑FDG activity over the entire body of the 
animals. B and D are sagittal sections of PET/CT images only in the heart area. In IM images, a spot‑pattern uptake can be clearly observed over 
myocardial wall (h), whereas IC administration showed a diffuse uptake. 18F‑FDG activity could also be clearly detected in bladder (b), kidneys (k) 
and lungs (l). Arrows point to lymph nodes with high 18F‑FDG uptake
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lungs. The signal accumulation in the lungs suggests that 
a percentage of cells were not retained at the heart, and 
were later entrapped in the lungs [13, 15, 16, 18]. It has 
been suggested that this largely right-sided distribution 
of cells, marked by pulmonary cell trapping far in excess 
of that by filter organs like liver and spleen, could be 
caused by an egress of cells into the myocardial venous or 
lymphatic drainage rather than into the arterial conduits 
[16]. Finally, the uptake in some mediastinal lymph nodes 
could be the result of lymphatic drainage from the injec-
tion site or the presence of some reactive lymph nodes.
Unlike cell retention, cell engraftment determined by 
immunohistological detection of GFP+-CSC at 3  days 
post-transplant showed significant differences between 
IC and IM administration. NOGA®-guided IM injection 
favored cell engraftment in comparison with IC injection 
as engrafted CSC were detected 3 days post-implantation 
in all the IM-implanted pigs whereas no cells were found 
in any of the IC-implanted animals. Although a certain 
degree of cell engraftment cannot be fully discarded, 
a clear discrepancy between the PET and histological 
results was found, which could be explained as a result 
of faster cell attrition after IC delivery. PET/CT images 
correspond to the first hours post-implantation, a phase 
in which cells are distributed and retained in the tissues. 
However, cells are swiftly and acutely lost from the tis-
sue due to mechanical washout, which impairs their per-
sistence and engraftment into the tissue, and that may 
depend on the chosen delivery route [13, 24]. In fact, the 
improved engraftment detected after NOGA®-guided IM 
cell injection is consistent with previous studies where 
several (stem) cell populations and several delivery routes 
Fig. 3 Correspondence between NOGA® and PET/CT images in IM administration: Three‑dimensional views derived by NOGA® endocardial map‑
ping showing peri‑infarct cell injections (A, B, brown spots). PET/CT images correspond to sections (not 3D projections) in the vertical long (C) and 
short axis (D) of the same pig. Focal uptake spots showed in 18F‑FDG PET/CT images correspond to the cellular injections
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(intravenous, IM or IC routes) have been comparatively 
analyzed in MI animal models. In those studies, a greater 
engraftment was found when using the IM route [3, 11]. 
Importantly, a greater functional improvement has been 
observed by others and also by our group when greater 
cell engraftment is achieved [20, 25–27]. In any case, 
although the direct correlation between engraftment 
and therapeutic benefit is expected, this does not nec-
essarily always correlate. In our study, a greater engraft-
ment was detected after IM injection. However, taking 
into account the similar rate of short-term retained cells 
and that the IC route allows a broader cells distribution 
(which could propitiate a short but robust paracrine 
effect of the implanted CSC [28]), functional long-term 
analysis will be also needed in order to confirm which cell 
delivery method might be more efficient as a therapeutic 
treatment. Therefore, we are performing new functional 
long-term studies in our animal model with that purpose. 
All this comparative data can be especially relevant in 
order to treat those patients, mainly the chronic ones, in 
which the coronary artery might be blocked and hence, 
it would not be possible to implant the cells via the IC 
route.
In this study, allogeneic instead of autologous cells 
were implanted. Limitations of the autologous approach 
related with the efficacy of the cells due to the patient´s 
age and disease as well as time, logistic and economic 
issues for cell production, makes of the allogeneic 
approach an interesting option for stem cell therapy. 
However, in the case of allogeneic treatments, the immu-
nogenic response may limit the time during which the 
cells may exert their effect. Therefore, the immunogenic 
profile that allows the cells to remain in the tissue is a 
key issue that needs to be elucidated in order to reach a 
Fig. 4 CSC acute retention and engraftment: PET quantitative results (a). Data is shown as %ID in every organ, after 4 h of IM (n = 3) or IC (n = 3) 
administration of 18F‑FDG labelled cells. Data is represented as mean plus standard deviation. Representative images of engrafted GFP+ cells in the 
heart (b). Tissue sections were immunohistochemically stained for detection of GFP+‑CSC (in brown), 3 days post‑implant. Positive cells were found 
in the hearts of all the IM implanted pigs, whereas no cells were found in any of the IC injected pigs. A representative picture (and magnification) 
shows the presence of engrafted CSC in the myocardium of an IM implanted pig
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beneficial effect. Importantly, we have previously dem-
onstrated the CSC tolerogenic immune behavior in the 
allogeneic setting [29]. CSC, as well as the mesenchymal 
stem cells, are characterized by the expression of HLA-
class I, but lack of expression of HLA-class II and the co-
stimulatory molecules CD40, CD80 or CD86. Previous 
in  vitro studies have also confirmed their low immuno-
genic profile, suggesting that CSC, although recognized 
by the immune system, will be initially tolerated [29]. 
Importantly, a functional benefit of the allogeneic CSC 
has been also demonstrated by our group in a preclini-
cal model of acute MI in pig [6]. All these data show the 
immunotolerogenicity of CSC which favors their reten-
tion despite their allogeneic origin and therefore, their 
therapeutic benefit. Interestingly, the immunotolerogenic 
capacity of our CSC population has been shown also in 
other CSC populations like the cardiosphere-derived 
cells. Also with this other particular cardiac cell popula-
tion, safety and a functional benefit has been shown after 
the allogeneic implant in rat and pig models of MI [30–
32]. In view of these results, two phase I/II clinical tri-
als (CAREMI trial (NCT: 02439398) and ALLSTAR trial 
[33]) are ongoing in order to determine the safety and 
efficacy of the allogeneic CSC and cardiosphere-derived 
cells respectively, as a treatment for patients with acute 
MI and ischemic left ventricular dysfunction.
Finally, this study has some limitations. On the one 
hand, although the data clearly show the different pat-
terns of cell biodistribution and retention, it would have 
been optimal to include a greater number of animals in 
order to perform a more robust statistical analysis. On 
the other hand, the use of 18F-FDG labeling to track stem 
cells offers some advantages like the simplicity of the 
labeling method, its great availability and the potential 
to track cells with PET/CT even in the clinical setting. 
However, this procedure presents some disadvantages 
that cannot be overlooked. First, 18F-FDG labeling only 
allows short-term tracking of the cells due to the half-
life of the tracer (T1/2 = 109.8 min) and second, 18F-FDG 
can in part be released from labeled cells. Classic meth-
ods for cell labeling in the clinical setting include the 
use of gamma emitting radioisotopes like Indium-111 
(T1/2 = 2.80 days). However, monitoring only can be per-
formed using single photon emission computed tomog-
raphy (SPECT/CT), a technique that provides images 
with significantly lower resolution and sensibility than 
those obtained by PET/CT. Very recently, some groups 
have developed different methods of cell labeling with 
89Zn, a positron emitter radionuclide with a longer half-
life (T1/2  =  78.4  h). Cell labeling strategies include the 
transport of 89Zr into cells in conjunction with oxine 
[34] or the direct labeling of cells surface by the creation 
of labeling entities with different chelators [35]. Those 
methods allow stable labeling of a wide range of cellu-
lar types that can be in vivo tracked by PET/CT imaging 
for up to 7 days. The development of cell labeling tech-
niques based on the use of other radiotracers like 52Mn 
(T1/2 = 5.6 days) is also under study [36]. In that sense, it 
would be interesting for future studies to use this type of 
radionuclides that would allow the assessment of longer-
term cell engraftment in our animal model.
Conclusion
In conclusion, we demonstrate that PET/CT images can 
accurately determine the biodistribution of 18F-FDG 
labeled cells in a large animal. Although acute retention of 
CSC is similar after either IM or IC implantation this does 
not translate into a similar level of cell engraftment, since 
this is greater after NOGA®-IM injection. Considering 
previous preclinical and clinical data that have shown the 
benefits of IC transplantation of CSC in acute MI in terms 
of safety and therapeutics [6], further research is needed 
to explore the comparative analysis of allogenic CSC deliv-
ered by NOGA®-IM injection for the chronic pathology.
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